low_ JAJP.qxd

Similar documents
Japanese Journal of Pesticide Science 42(1): (2017)

LCMS14003:UHPLC-Orbitrap質量分析計による環境汚染物質のターゲット分析、ノンターゲット分析

2 (FDA) 1 1 A D E K 1 LC UV 15 HPLC 3.5 UHPLC Agilent 12 Infinity LC Agilent 12 Infinity (G1311B) Agilent 12 Infinity (G13E) Agilent 12 Infinity (G131

MassHunter Workstation Agilent MassHunter Workstation MS Agilent TOF Q-TOF LC/MS LC/MS GC/MS ICP-MS Agilent MS * MassHunter Workstation LC/MS GC/MS IC

GPC/SEC

Metabolomic Profiling_JA.qxp

Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPL

LC/TOF-MS MS ( )

JAJP.qxp

JAJP.qxp

☆H23 13-農薬一斉分析(大垣).doc

平成26年度 化学物質分析法開発報告書

食糧 その科学と技術 No.46( )


平成26年度 化学物質分析法開発報告書

ソリッドコアUHPLCカラムとUHPLCシステム、質量分析計を利用した違法薬物の高速スクリーニング分析

JAJP.qxp

HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HIL

<4D F736F F D F90858C6E5F C B B B838B>

JP.qxd

SEC (SEC) SEC SEC SEC 2

1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C) Thiamine (B1) Nicotinic Acid (B3) Pyridoxal (

JAJP

qxd

<4D F736F F D C6E30385F A B B83932E444F43>

Microsoft Word - 14_LCMS_アクリルアミド

untitled

Agilent Infinity ELSD ELSD ( ) ( ºC ) W x D x H mm LED ELSD ELSD ELSD UV UV LC/MS RSD % Column: Agilent Pursuit C8, x.6 mm, µm Eluent: Water: Acetonit

Agilent RapidFire 365 ハイスループット質量分析システム 創薬プロセスを加速する HTS システムテクノロジー

2 Agilent OpenLAB CDS OpenLAB CDS OpenLAB CDS OpenLAB IT 2

スライド 1

平成26年度 化学物質分析法開発報告書

Group A (2,5-Dimethoxyphenyl type) 25D-NBMe (1) 25B-NBMe (2) 25I-NBMe (3) 25C-NBF () 25B-NBF (5) Group B (Benzofuran-2-yl type) Group C (-Alkoxy-3,5-d

UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC

LC LC ACQUITY UPLC H-Class ACQUITY UPLC CSH C mm 1.7 µm : THF/ 2/8 A 1 mm / 4/6 THF 2 mg/ml THF/ 2 THF 2 ACQUITY UPLC CSH C 18

Agilent 7900 ICP-MS 1 1 Ed McCurdy 2 1 Agilent Technologies, Japan 2 Agilent Technologies, UK

Agilent AA ICP ICP-MS ICP-MS AA 55B AA LCD AA PC PC 240 AA / / AA 240FS/280FS AA AA FS 240Z/280Z AA GFAA AA Duo 1 PC AA 2 280FS AA

パーキンソン病治療ガイドライン2002

Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B

研修コーナー

: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 )

Agilent BioHPLC HPLC/UHPLC /

ヒト血漿中オキシステロールの高感度分析法

Ⅱ6.3界面活性剤

JAJP.indd

JAJP.qxd

untitled

(EQP) (DQ) (IQ) (OQ) OQ (RQ) IQ OQ IQ OQ (ACE) OQ EQP EQP Adobe (i) Q & A (ii) Agilent Compliance Engine (ACE) - 21 CFR Part11 (iii) EE 1.76 EQR 3 PDF

(DHA) µg/ml 2,3 4 DHA AOAC DHA C UVDHA 22 nm ph nm 5 AOAC UV UV HPLC Milli Q (Millipore Elix 1 ) Lab-Scan ( ) Fluka () o-

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)


ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB 3.

橡マニュアルv4c.PDF

バイオ解析チーム教育セミナーMS04

untitled

untitled

14 : : : : : : 00 LC/MS/MS 1, : : 00 Novel strategies and applications of enhanced shotgun lipidomics for

X線分析の進歩36 別刷

JAJP.indd

2006 E. coli 7000 (AP ) (CNN) 2008 (Farm Press) 200 (Time) 2

xxxxEN.qxd

ICP-OES ICP-MS

第86回日本感染症学会総会学術集会後抄録(I)

Agilent OpenLAB CDS ChemStation OpenLAB CDS ChemStation Lab Advisor Secure Workstation Data Store OpenLAB ECM OpenLAB C A P T U R E A N A L Y Z E S H

Bond Elut 25%OFF Bond Elut 25 %OFF Bond Elut, Mega Bond Elut Bond Elut AL-A Bio Bond Elut Bond Elut AccuCAT Bond Elut Carbon Bond Elut Atrazine Bond E

第90回日本感染症学会学術講演会抄録(I)

Ł\”ƒ-2005

(2/27) AV OA

Agilent

Microsoft Word - 5MS.doc

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)


合成カンナビノイドJWH-018、JWH-073、JWH-122及びそれらの異性体の識別


1 Q A 82% 89% 88% 82% 88% 82%

pera1会社概要n

要調査項目等調査マニュアル


2

_FH28_J.qxd

3 1 2

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)

Microsoft Word - 14_LCMS_アクリルアミド



製紙用填料及び顔料の熱分解挙動.PDF

表 1. HPLC/MS/MS MRM パラメータ 表 2. GC/MS/MS MRM パラメータ 表 1 に HPLC/MS/MS 法による MRM パラメータを示します 1 化合物に対し 定量用のトランジション 確認用のトランジションとコーン電圧を設定しています 表 2 には GC/MS/MS

PowerPoint プレゼンテーション

% 1% SEM-EDX - X Si Ca SEM-EDX SIMS ppm % M M T 100 % 100 % Ba 1 % 91 % 9 % 9 % 1 % 87 % 13 % 13 % 1 % 64 % 36 % 36 % 1 % 34 46

PowerPoint プレゼンテーション

日本化学療法学会雑誌第51巻第2号

untitled

untitled

untitled


SEC SEC ESIMS SEC/ESIMS 6), 7) Fig. 1 LC Pump for addition 5µL/ NaI NaI 15Da KIKI 166Da PMMA KCl PMMA SEC System(Agilent 11 LC) Fig. 1.25mL/ THF Agile

細辛 (Asari Radix Et Rhizoma) 中の アサリニンの測定 Agilent InfinityLab Poroshell 120 EC-C µm カラム アプリケーションノート 製薬 著者 Rongjie Fu Agilent Technologies Shanghai

LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY

バイアル新規ユーザー様限定 ガラス製容器 -Si-O H シラノール -Si-O H -Si O -Si イオン的吸着 疎水的吸着シロキサン logp pka + N 塩基性化合物 疎水的吸着 水溶液 P P 製容器, 7,7

C:CAD?????????w???W??KUT?????????4?N?????O???I??1?O_?I??1?i???jweb?p.IPO

Transcription:

LC/MS Chad Borges, Matthew Slawson, James Taccogno, and Dennis Crouch Center for uman Toxicology University of Utah Salt Lake City, UT USA John M. ughes Agilent Technologies, Inc. Pleasanton, CA USA (oa-tof) Agilent LC/MSD TOF 1 2 ng/ml 4 1 TOF (2 ppm ) (EIC) LC/MSD TOF EIC 1.8 C18 [1 3] ( BALCO TG ) / (GC/MS) [2] EI GC/MS [4] GC/MS [5] GC/MS GC/MS GC/MS (SRM) (MRM) / (LC/MS) [6]

API LC/MS 40 GC/MS LC/MS [7] 2 -ng/ml [ (WADA) (MRPL)] WADA MRPL Agilent LC/MSD TOF 1 (ISTD) (ESI) APCI APCI ESI (Na + K + ) APCI 1 APCI ESI O Cl 2 N Cl N 3 C C 3 C 3 O Clenbuterol 19-norandrosterone N N 3 C 3 C C 3 O C 3 O C 3 3'- stanozolol 3 C 3 C Methyltestosterone (internal standard) Methyltestosterone metabolite (17α-methyl-5β-androstane-3α,17β-diol) C 3 O O Epitestosterone Epimetendiol (methandrostenolone metabolite) 1. 2

[M+] + m/z 121.050873 922.009798 2 ( P-921) LC MS APCI 1 GC/MS the Center for uman Toxicology, Sports Medicine Research and Testing Laboratory LC/MS GC/MS 3 ml (10 ng/µl 20 µl) 0.15 M 1mL p 5 Extrelut-3 (MerckVMR 48219-494 100 ) 1 g SPE (J.T.Baker VMR J7088-3 50 ) 8 9 ml 13 x 100 mm LC/MS 40 Agilent laboratory (Pleasanton, CA) -10 100 µl LC LC/MS API-TOF Agilent 1100 LC ( UV-VIS ) G1969A LC/MSD TOF ESI APCI Agilent 1. LC : Agilent ZORBAX RRT SB-C18 2.1 50 mm 1.8 µm (Agilent 822700-902) : A = 0.1% / B = : 0.4 ml/min : 55 ºC : 55% B 5 55% 75% B (5 9 ) : 14 : 5 : 4 µl MS : APCI () : 3,500 V : 450 ºC : 4 µa : : 60 psig 5 L/min : 350 ºC : : : : LC/MS m/z 100 1000 10,000 / (0.89 /) 121 922 (5 µl/min 10 µm ) 150 V [ (CID) ] 60 V ( ) RF: 250 V ( ) 3

API-TOF LC/MS GC/MS LC/MS m/z 7,000 2 ppm MRM-MS/MS MS/MS / () ESI 2 ppm [M+] + m/z APCI APCI APCI ESI (Na + K + ) 2 (3 ml 16 ng/ml ) 15 / Base Peak Chrom. of +TOF MS: from steroid2tofap42.wiff Intensity, cps 1.3e5 1.2e5 1.1e5 1.0e5 9.0e4 8.0e4 7.0e4 6.0e4 5.0e4 4.0e4 3.0e4 2.0e4 1.0e4 0.530 Clenbuterol 3 stanozolol 2.620 5.478 Epitestosterone MeTestosterone (IS) 0.0 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 Time, min 5.749 6.625 8.086 19-norandrosterone MeTestosterone metabolite Epimetendiol 11.064 2. ( 16 ng/ml ()) 4

(CID) CID 50V LC/MSD TOF 3 APCI [M+] + [M+-18] + [M+] + -1.04 ppm 3 [M+] + 6,890 [M+] + m/z 290 13 C m/z 289.2159 (R)m/z (FWM w 1/2 Da) R = M/w 1/2 M = 289.2159M ( ) w 1/2 = 0.042 Da R = 289.2159/0.042 = 6890 13 C [M+] + Intensity, counts 1.10e5 1.00e5 9.00e4 8.00e4 7.00e4 6.00e4 5.00e4 4.00e4 3.00e4 2.00e4 1.00e4 0.00 +TOF MS: 5.474 to 5.547 min from steroid2tofap42.wiff Agilent, subtracted (4.696 to... 120 Epitestosterone, MW 288, Expected (M+) + 289.2162 Observed (M+) + 289.2159 Mass accuracy (mass error) = (mass obs _ massexp )/mass exp ) 10 6 (289.2159 _ 289.2162)/289.2162) 10 6 = _ 1.04 ppm 271.2051 269.1893 289.2159 287.1997 Max. 1.2e5 counts. +TOF MS: 5.474 to 5.547 min from steroid2tofap42.wiff 140 160 180 200 220 240 260 280 300 320 340 360 380 400 m/z, amu Intensity, counts 1.10e5 1.00e5 9.00e4 8.00e4 7.00e4 6.00e4 5.00e4 4.00e4 3.00e4 2.00e4 1.00e4 0.00 289.2159 289.4107 Max. 1.2e5 counts. Resolution 6890 [(m/z)/w 1/2 ] 290.2190 288.0 288.5 289.0 289.5 290.0 290.5 291.0 291.5 292.0 m/z, amu 3. APCI TOF [M+] + = 289.2162 m/z 271.2051 5

(m/z 271 ) 19- [ 4] m/z 259.2049 241.1949 1 2 ESI 4 121 922 LC T MS 2 P-921 (Agilent API ) LC/MSD TOF 5.0e4 4.5e4 4.0e4 +TOF MS: 6.596 to 6.650 min from steroid2tofap42.wiff Agilent, subtracted (7.374 to... 241.1949 Observed (M+ _ 2 2 O) + m/z 241 Resolution 6403 _ 0.73 ppm 19-norandrosterone, MW 276 3.5e4 259.2049 Intensity, counts 3.0e4 2.5e4 2.0e4 Ref mass 8000 counts Observed (M+ _ 2 O) + m/z 259 Resolution 6464 _ 2.86 ppm 1.5e4 1.0e4 121.0502 Ref mass 8000 counts 922.0080 5000.0 0.0 200 300 400 500 600 700 800 900 1000 m/z, amu 4. 19-276 2 m/z 121 922 6

19-50 ng/ml ISTD 66 ng/ml 5 3' - (EIC) Base Peak Chrom. of +TOF MS: from steroid2tof092007.wiff Intensity, counts 3.0e6 2.8e6 2.6e6 2.4e6 2.2e6 2.0e6 1.8e6 1.6e6 1.4e6 1.2e6 1.0e6 8.0e5 6.0e5 4.0e5 2.0e5 0.0 0.535 4.207 Epitestosterone+IS 19-norandrosterone 4.958 6.333 MeTestosterone metabolite 11.352 Epimetendiol 0 2 4 6 8 10 12 14 Time, min 5. 50 ng/ml 7

2 ng/ml 19-1 ng/ml (MRPL) EIC 6 EIC 50,000 100,000 S/N EIC TOF EIC 1 mda ( 3 ppm) 19-241.1949 [M+ - 2 2 O] + EIC 241.1944 241.1954 TOF S/N 19-6. 2 ng/ml(19-1 ng/ml) EIC (1 mda ) 8

6 7 TOF 100% 240 pg (19-120 pg) 2 ppm (IS): -0.33 ppm : 1.59 ppm 19- : 1.99 ppm : 1.84 ppm : 1.78 ppm 7. 2 ng/ml (19-1 ng/ml) ( 240/120 pg) [ 6 ] 9

LC/MSD TOF 19- ( 3 ml 0.16 ng/ml ) 20 pg 4 µl (1 mda ) EIC 8 S/N 1.8 -µm 3.5 -µm 1.8 -µm 19-8. 0.16 ng/ml ( 20 pg) EIC (1 mda ) 10

GC/MS () API-TOF LC/MS 1 2 ng/ml LC/MSD TOF EIC S/N 100 µl 4 µl 1 EIC (m/z 1 mda EIC) ng/ml 2 ppm 1. A. Leinonen, T. Kuuranne, T. Kotiaho, and R. Kostiainen, Screening of unconjugated anabolic steroids in urine by liquid chromatography/ mass spectrometry. In W. Schanzer,. Geyer, A. Gotzmann, and U. Mareck, Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, 163. 2.. Pereira, M. Marques, I. Talhas, and F. Neto, Analysis of androgenic steroids, beta-2-agonists and other substances by GC-MS-ITD. In W. Schanzer,. Geyer, A. Gotzmann and U. Mareck, Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, 259. 3. T. uynh, G. Trout, and R. Kazlauskas, The detection of low level anabolic agents in bovine and human urine using LC-ESI-MS-MS. In Recent advances in doping analysis. (2003) Sport und Buch Straub, Koln, 11, 271. 4. G. Trout, S. Soo, and R. Kazlauskas, Single screen for steroids using RMS. In Recent advances in doping analysis, (2003) Sport und Buch Straub, Koln, 11, 249. 5. I. Ojanpera, A. Pelander, S. Laks, M. Gergov, E. Vouri and M. Witt, Application of accurate mass measurement to urine drug screening. (2005) J Anal Tox, 29, 34. 6. L. Politi, A. Groppi, and A. Polettini, Application of liquid chromatography-mass spectrometry in doping control. (2005) J Anal Tox, 29, 1. 7. M. Gergov, I. Ojanpera and E. Vuori, Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple reaction monitoring. (2003) J Chrom B, 795, 41. Agilent Technologies, Inc. John ughes Agilent (www.agilent.com/chem/jp) 11

www.agilent.com/chem/jp Agilent 0120-477-111 Agilent Technologies, Inc. 2006 Printed in Japan March 20, 2006 5989-4738JAJP